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The Use of High-Flow Nasal Oxygen in
the ICU as a First-Line Therapy for Acute
Hypoxemic Respiratory Failure Secondary to
Coronavirus Disease 2019
Gregory McDonough, MD1; Phue Khaing, MD1,2; Taylor Treacy, BMSc3; Christopher McGrath, MD1,2;
Erika J. Yoo, MD1,2

Objectives: Limited evidence is available regarding the role of highflow nasal oxygen in the management of acute hypoxemic respiratory
failure secondary to coronavirus disease 2019. Our objective was to
characterize outcomes associated with high-flow nasal oxygen use in
critically ill adult patients with coronavirus disease 2019-associated
acute hypoxemic respiratory failure.
Design: Observational cohort study between March 18, 2020, and
June 3, 2020.
Setting: Nine ICUs at three university-affiliated hospitals in
Philadelphia, PA.
Patients: Adult ICU patients with confirmed coronavirus disease
2019 infection admitted with acute hypoxemic respiratory failure.
Interventions: None.
Measurements and Main Results: Of 266 coronavirus disease
2019 ICU admissions during the study period, 124 (46.6%)
received some form of noninvasive respiratory support. After
exclusions, we analyzed 83 patients who were treated with highflow nasal oxygen as a first-line therapy at or near the time of ICU
admission. Patients were predominantly male (63.9%). The most
common comorbidity was hypertension (60.2%). Progression
to invasive mechanical ventilation was common, occurring in 58

patients (69.9%). Of these, 30 (51.7%) were intubated on the
same day as ICU admission. As of June 30, 2020, hospital mortality rate was 32.9% and the median hospital length of stay was 15
days. Among survivors, the most frequent discharge disposition
was home (51.0%). In comparing patients who received high-flow
nasal oxygen alone (n = 54) with those who received high-flow
nasal oxygen in conjunction with noninvasive positive-pressure
ventilation via face mask (n = 29), there were no differences in
the rates of endotracheal intubation or other clinical and utilization
outcomes.
Conclusions: We observed an overall high usage of high-flow nasal
oxygen in our cohort of critically ill patients with acute hypoxemic
respiratory failure secondary to coronavirus disease 2019. Rates of
endotracheal intubation and mortality in this cohort were on par with
and certainly not higher than other published series. These findings
should prompt further considerations regarding the use of high-flow
nasal oxygen in the management algorithm for coronavirus disease
2019-associated acute hypoxemic respiratory failure.
Key Words: coronavirus; critical care; high-flow nasal oxygen;
intubation, intratracheal; noninvasive ventilation; respiratory distress
syndrome, adult
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Critical Care Explorations

he role of noninvasive respiratory support strategies in the
management of acute hypoxemic respiratory failure (AHRF)
secondary to coronavirus disease 2019 (COVID-19)
is not well defined. Early in the pandemic, anecdotal guidance
favored early endotracheal intubation, given rapidly escalating
oxygen requirements seen in infected individuals and concerns
for viral aerosolization with the use of high-flow nasal oxygen
(HFNO) or noninvasive positive-pressure ventilation (NIV). As
international experience with COVID-19 has grown, there have
been calls for a more nuanced approach to decisions regarding endotracheal intubation, with more consideration given to
www.ccejournal.org
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noninvasive respiratory support strategies early in the disease
course (1, 2).
The optimal mode of noninvasive respiratory support in
COVID-19-associated AHRF is unknown. The Society of Critical
Care Medicine recommends HFNO over NIV for COVID-19associated AHRF (3). However, due to lack of data specific to
COVID-19, this recommendation comes as an extrapolation of
evidence from other critically ill patient populations. HFNO in
particular has been shown to be effective in preventing reintubation in other non-COVID disease states (4, 5) and may even confer a mortality benefit compared with standard oxygen therapy or
NIV when applied to patients with nonhypercapnic acute respiratory failure (6). Among COVID-19 patients, successful treatment with HFNO and avoidance of intubation has been reported
among patients with less severe hypoxemia in a small study from
China (7). Utilization of HFNO, however, appears variable in clinical practice, with only 5% trialed on this modality in a New York
City COVID-19 cohort and 21% in an early cohort of hospitalized
patients from Wuhan, China (8, 9). Overall, experiences with use
of HFNO in COVID-19-associated AHRF have not been extensively described in the literature.
In light of evolving opinion and limited evidence, we sought to
describe the characteristics and outcomes of adult patients with
AHRF secondary to COVID-19 who were treated with HFNO as
a first-line therapy at or near the time of ICU admission.

MATERIAL AND METHODS

This is an observational cohort study of critically ill patients with
COVID-19-associated AHRF who received HFNO as a first-line
therapy at or near the time of ICU admission. This cohort was
screened from a larger cohort of critically ill patients with COVID19 who were admitted to nine ICUs (99 beds) at three Thomas
Jefferson University hospitals in Philadelphia, PA, between March
18, 2020, and June 3, 2020. All patients had laboratory-confirmed
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection via polymerase chain reaction assay of primarily nasopharyngeal swabs, with the adjunct of lower respiratory tract
aspirates, as clinically indicated. During the time of this study,
all patients were managed under a high-intensity ICU model of
staffing, irrespective of the unit to which they were admitted (10).
There were no critical shortages in beds, staffing, ventilators, or
other supplies.
Patients were included if they received HFNO alone, or HFNO
in sequential conjunction with NIV delivered by face mask, as a
first-line therapy at or near the time of ICU admission. The decision
to initiate HFNO as well as the individual settings of the HFNO
device (Fisher & Paykel, Auckland, New Zealand, or Vapotherm,
Exeter, NH) were at the discretion of the attending physician. We
excluded patients with limitations to their care at ICU admission
(e.g., do not resuscitate [DNR] and/or do not intubate [DNI]), as
this may have affected the decision to use noninvasive respiratory
support strategies. We also excluded patients who received NIV
alone in our analyses to avoid patients with hypercapnia as the
primary driver of their respiratory failure. The primary outcome
of interest was progression to invasive mechanical ventilation.
2
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Secondary outcomes included ICU and hospital mortalities and
length of stay (LOS).
Clinical, demographic, and therapeutic data were chartabstracted from the electronic medical record and stored in a
password-protected online data repository, research electronic
data capture, accessible to key study personnel (11). To compare
patients who received HFNO alone with those who received
HFNO in sequential conjunction with NIV, we used chi-square
or Fisher exact for categorical variables, and Wilcoxon rank-sum
for continuous variables, as appropriate. A two-sided p < 0.05 was
considered statistically significant. Statistical analyses were performed with Stata 15.1 (Statacorp, College Station, TX). The study
was approved by Jefferson’s Office of Human Research Institutional
Review Board (20E.414) with a waiver of informed consent.

RESULTS
Admission Characteristics
From March 18, 2020, to June 3, 2020, there were 266 admissions
to the ICU for patients infected with SARS-CoV-2, of which 15
(5.6%) were nonindex ICU admissions (i.e., readmissions to the
ICU during the same hospital stay). Overall, 124 (46.6%) of all
COVID-19 ICU admissions received some form of noninvasive
respiratory support at the time of or immediately prior to ICU
admission. After exclusions, we identified 83 patients who were
treated with HFNO as a first-line therapy, of which 54 received
HFNO alone and 29 received HFNO in sequential conjunction
with NIV (Fig. 1).
Patient characteristics of the HFNO cohort are summarized in
Table 1. Among these 83 patients, the median age was 65 years
(interquartile range [IQR], 55–76), with 54.2% of patients 65
years old or older. Patients were predominantly male (63.9%) and
Black (44.6%). The most common comorbidity was hypertension
(60.2%), followed by diabetes mellitus (53%). Other chronic illnesses such as malignancy, cerebrovascular accident, and endstage renal disease were uncommon. Most patients in the study
originated from the floor rather than directly from the emergency
department prior to ICU admission.
The median Acute Physiology and Chronic Health Evaluation
(APACHE) II score in this cohort was 23 (IQR, 16–30). Nearly
all patients had inflammatory markers drawn, the median
peak values of which were elevated far above reference ranges
(Table 2).
Interventions and Outcomes
Systemic anticoagulation was newly started in 24 patients (28.9%),
with venous thromboembolic events (i.e., pulmonary embolism or
deep vein thrombosis) confirmed in six patients (7.2%). Systemic
steroids were newly administered in 38 patients (45.8%), with the
predominant indication for steroids being COVID-19 pneumonia
(22, 57.9%) (Table 2).
Progression to invasive mechanical ventilation was common and occurred in 58 patients (69.9%) (Table 3). Of these, 30
(51.7%) were intubated on the same day as ICU admission. The
median postintubation Pao2:Fio2 ratio was 130 mm Hg (IQR, 97–
210) (Table 2). The median duration on the ventilator was 9 days
2020 • Volume 2 • e0257
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APACHE II scores between the two
groups. Postintubation Pao2:Fio2
ratios were significantly lower
among patients who received HFNO
in conjunction with NIV, and these
patients were also more likely to
receive inhaled vasodilator therapy.
New systemic anticoagulation and
systemic steroids were administered
equally between the two groups
(Table 4).
Neither category of noninvasive respiratory support was more
successful at preventing or delaying
endotracheal
intubation.
Furthermore, there was no significant difference in the duration of
invasive mechanical ventilation, tracheostomy rates, ICU and hospital
mortality, and ICU and hospital LOS
between the two groups (Table 4).

DISCUSSION

During the initial COVID-19 experience at our institution, we demFigure 1. Patient-selection process. COVID-19 = coronavirus disease 2019, DNI = do not intubate,
onstrated an overall high usage of
HFNO = high-flow nasal oxygen, NIV = noninvasive positive-pressure ventilation.
noninvasive respiratory support
modalities for critically ill patients
(IQR, 4.5–24.5 d), and tracheostomy was ultimately performed in with AHRF secondary to COVID-19. Nearly half of all COVID-19
17 patients (29.3%) (Table 3).
ICU admissions received some degree of noninvasive respiratory
As of June 30, 2020, one patient remained admitted to the ICU support in the form of HFNO and/or NIV as a first-line therapy,
on invasive mechanical ventilation, and six additional patients
and 96 patients (36.1%) were treated, at least in part, with HFNO
were still hospitalized after leaving the ICU. Among patients with
at or near the time of ICU admission.
available discharge data, ICU mortality was 29.3% (24/82) and
After exclusions of patients with care limitations, we analyzed
overall hospital mortality was 32.9% (25/76). The mortality out- 83 ICU admissions (31.2%), in which HFNO was employed as a
comes of these patients who received HFNO as first-line therapy first-line therapy, alone or in sequential conjunction with NIV via
did not differ significantly from those who received no noninface mask. We showed that progression to invasive mechanical
vasive respiratory support at or near the time of ICU admission
ventilation was common and occurred early. However, despite a
(Supplemental Table 1, Supplemental Digital Content 1, http:// high index of illness severity recorded at ICU admission, approxilinks.lww.com/CCX/A387). At the time of death in the ICU, 21 mately two-thirds of patients survived to hospital discharge, and
patients (87.5%) had some form of care limitations (e.g., DNR/ among these survivors, over half returned to home. We additionDNI or withdrawal of life support). Median ICU and hospital LOS
ally showed that there were no differences in outcomes among
were 9 days (IQR, 4–17 d) and 15 days (IQR, 10–26.5 d), respec- patients who received HFNO alone, compared with those who
tively. Among survivors to hospital discharge, the most frequent
received HFNO in sequential conjunction with NIV.
discharge disposition was home (51.0%), followed by acute rehaThe high utilization rate of HFNO seen in our study difbilitation facility (27.5%) (Table 3).
fers considerably from the 5% reported in a New York City ICU
cohort during their regional peak of the pandemic (8). Similarly,
Comparison of HFNO-Alone Group With HFNO + NIV
in an ICU cohort from Tongji, China, only 10.2% of patients were
Group
treated with HFNO (12). In Lombardy, Italy, 137 critically ill
We conducted additional analyses to compare the 54 patients who
patients (11%) used some form of noninvasive support, although
received HFNO alone with the 29 patients who received HFNO
it is uncertain where HFNO fell into their care algorithm (13).
in sequential conjunction with NIV. Demographics were similar It is possible that the higher HFNO utilization in our cohort is
between the two groups, as were comorbidities, with the exception
explained by the timing of the onset and peak of the pandemic
of heart failure, which was more common in the group to which
in Pennsylvania, which lagged that of China, Italy, and even New
NIV was also applied. There was no difference in the median
York by at least a month or more. As such, there may have been
Critical Care Explorations
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TABLE 1. Patient Demographic and Admission
Characteristics
Characteristic (n [%] Unless
Otherwise Indicated)

Age, median (IQR)
Age ≥ 65

Total (n = 83)

65 (55–76)
45 (54.2)

Male

53 (63.9)

Race

Laboratory values,a median (IQR)

Peak C-reactive protein
(mg/dL)

26.9 (15.6–34.7)

≤ 0.80

13 (15.7)

Peak ferritin (ng/mL)

Asian/Pacific-islander

1 (1.2)
29.3 (24.9–33.5)
36 (43.4)

Smoking status

Pao2:Fio2, median (IQR)
b

1,375 (763–2,507) 30–400
130 (97.0–210.5)

Interventions
Inhaled pulmonary vasodilator

9 (10.8)

New systemic anticoagulation

24 (28.9)

Active

5 (6.0)

New systemic steroids

38 (45.8)

Former

35 (42.2)
36 (43.4)

New initiation of renal
replacement therapy

9 (10.8)

Never
Unknown

7 (8.4%)

Comorbidities
Hypertension

50 (60.2)

Diabetes mellitus

44 (53.0)

Congestive heart failure

18 (21.7)

Chronic obstructive pulmonary disease/
asthma

16 (19.3)

Coronary artery disease

15 (18.1)

Cancer

9 (10.8)

Cerebrovascular accident

7 (8.4)

End-stage renal disease

5 (6.0)

Nonindex ICU admission

4 (4.8)

Admission source
Home

64 (77.1)

Nursing home

14 (16.9)

Other/unknown

5 (6.0)

Care site immediately prior to ICU
Floor

47 (56.6)

Emergency department

27 (32.5)

Step-down unit

9 (10.8)

Symptom duration prior to presentation (d)
<7

40 (48.2)

7–14

31 (37.3)

> 14

5 (6.0)

Unknown

7 (8.4)

IQR = interquartile range.

4

23 (16–30)

11 (13.3)

21 (25.3)

Hispanic

≥ 30 kg/m

www.ccejournal.org

Reference
Range

< 230

White

2

Acute Physiology and Chronic
Health Evaluation II score,
median (IQR)

Total
(n = 83)

4,502
(1,946–14,613)

37 (44.6)

Body mass index, median (IQR)

Characteristic (n [%] Unless
Otherwise Indicated)

Peak d-dimer (ng/mL)

Black

Other/unknown

TABLE 2. Clinical Characteristics and ICU
Interventions

Prone ventilation
Extracorporeal membrane
oxygenation

28 (48.3)
2 (2.4)

IQR = interquartile range.
a
Three missing values.
b
Postintubation values only, two missing values.
c
Refers to % proned in 58 mechanically ventilated patients only.

increased comfort with trialing noninvasive respiratory strategies
due to this delay and, in the setting of absent evidence, a willingness to gauge its impact on patient outcomes.
It remains unknown whether HFNO in COVID-19-associated
AHRF can prevent progression to invasive mechanical ventilation or affect overall mortality. At our institution, the endotracheal intubation rate for the entire ICU cohort prior to exclusions
was approximately 70%, which is on the lower end of the 75–88%
range reported in other published COVID ICU cohorts, both
domestically and abroad (8, 13–15). In our analyzed cohort of 83
patients with no care limitations, who received HFNO as a firstline therapy on ICU admission, the overall endotracheal intubation rate was 69.9%. Additionally, the ICU mortality rate of 29.3%
in our cohort of HFNO patients is significantly lower than previously reported mortality rates, which have ranged from 42.5% to
78% among other COVID-19 ICU patient cohorts (13, 16, 17).
The reason for our lower observed rates of endotracheal intubation without a higher ICU mortality compared with other published reports is unclear and may be multifactorial. At the very
least, our findings are encouraging in that patients with COVID19-associated AHRF who received HFNO as a first-line therapy
did not have worse outcomes. Optimistically, our findings may
perhaps even suggest that patients with COVID-19-associated
AHRF who receive HFNO as a first-line therapy may have better
2020 • Volume 2 • e0257
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TABLE 3.

Clinical Outcomes

Outcome (n [%] Unless Otherwise Indicated)

Invasive mechanical ventilation

Total (n = 83)

58 (69.9)

Time to intubation (d), median (IQR)

0 (0–1)

Ventilator days, median (IQR)

9 (4.5–24.5)

a

17 (29.3)

Tracheostomy

b

ICU mortality

24 (29.3)

Hospital mortality

25 (32.9)

ICU LOS (d), median (IQR)

9 (4–17)

a

Hospital LOS (d), median (IQR)
c

15 (10–26.5)

Hospital discharge disposition

c,d

Home

26 (51.0)

Long-term acute care

5 (9.8)

Skilled nursing facility

5 (9.8)

Rehabilitation facility

14 (27.5)

Nursing home

1 (2.0)

IQR = interquartile range, LOS = length of stay.
a
Excludes one patient still on mechanical ventilation in the ICU as of June 30,
2020.
b
Refers to % tracheostomized in 58 mechanically ventilated patients only.
c
Excludes seven patients still hospitalized as of June 30, 2020.
d
Refers to disposition among survivors to hospital discharge only.

outcomes than initially expected based on anecdotal guidance
early in the pandemic. This should prompt clinicians and researchers to explore further as to when, for whom, and how HFNO can
be used in the algorithm for AHRF in COVID-19.
The relative benefits of various noninvasive respiratory support strategies for the management of (non-COVID-19) AHRF
have previously been explored. Although the landmark high FLow
nasal Oxygen in the Resuscitation of patients with Acute Lung
Injury trial in 2015 popularized the use of HFNO in the treatment
of AHRF by showing a reduction in 90-day mortality, the primary
outcome of progression to endotracheal intubation was not significantly different between the use of HFNO, NIV, and standard
oxygen therapy in this study (6). Likewise, other randomized controlled trials exploring whether HFNO can prevent endotracheal
intubation compared with other noninvasive modalities have
additionally produced conflicting results (18–22). These varying findings are likely due to the heterogeneity that exists in the
underlying etiologies and clinical courses of AHRF, coupled with
the heterogeneity in the studies comparing various combinations
of noninvasive respiratory support modalities (e.g., HFNO vs NIV
via face mask, or HFNO vs standard oxygen therapy) (23). These
nuances may be especially important to consider with a novel
respiratory disease such as COVID-19, which may have its own
unique phenotype(s) (24, 25). Thus, beyond the findings from
our study, further investigation is warranted to guide clinicians in
understanding the role of HFNO and/or NIV in potentially delaying or avoiding endotracheal intubation without sacrificing favorable patient outcomes.
Critical Care Explorations

One major concern among clinicians with using HFNO in
AHRF secondary to COVID-19 is the possible risk of increased
aerosolization of viral particles. However, it remains unknown
how significant this risk may be. At our institution, it is unknown
whether any cases of healthcare worker infection could be directly
linked to HFNO exposure. It has been suggested that the aerosolization of respiratory particles with HFNO is similar to that of other
oxygen support modalities such as a standard oxygen mask (26).
Similarly, a recent systematic review could not identify demonstrative evidence in either support or rejection of this concern (27). A
salient risk factor for nosocomial infections of healthcare workers
described during the current COVID-19 pandemic has included a
lack of proper personal protective gear, and infections were more
likely to occur earlier in the pandemic when preparations of personnel and resources were likely to have been archaic (28). In this
context, HFNO should continue to be viewed as a viable strategy
for use in AHRF secondary to COVID-19, but one that needs further exploration of the risk-benefit scale in terms of patient outcomes, local resources, and healthcare worker safety.
Our study has several limitations, including its retrospective
nature. First, the utilization of HFNO with NIV was not protocolized. Although many patients were often stepped-up to NIV
from HFNO at or near the time of ICU admission, the order and
duration of use of either modality were at the discretion of the treating physician. The sequential and alternating use of HFNO and NIV
has been examined in its ability to affect patient comfort, ventilatory
parameters, and oxygenation in non-COVID AHRF, but not rates
of intubation (29). Our descriptive study also precludes conclusions
about whether their dual use can avoid intubation in some patients.
Second, our study took place at three hospitals in Philadelphia, PA,
potentially limiting generalizability to other institutions serving
patients with differing demographics and socioeconomic vulnerabilities. Additionally, locoregional differences in the availability
of personnel and hospital resources could affect viability of using
HFNO during a pandemic surge. Finally, because our focus was on
COVID-19 patients with ICU needs, it is possible that more patients
successfully treated with HFNO were kept on the wards and, therefore, were not included in our analyses.

CONCLUSIONS

In our critically ill cohort of patients with AHRF secondary to
COVID-19, we saw high rates of HFNO utilization, with intubation and mortality rates that were on par with and certainly not
higher than other published series. Some have argued that the risk
of spontaneous respiratory efforts in AHRF may, at times, preclude
consideration of noninvasive strategies (30). However, the avoidance of invasive mechanical ventilation along with its inherent
complications is not an unreasonable approach in select patients.
Our study findings should prompt clinicians and researchers
to explore further the role of HFNO as a viable strategy in the
algorithm for COVID-19-associated AHRF. As the decision to
intubate patients with AHRF is clinical, often based on physician
judgment, further trials examining the use of HFNO specifically
in COVID-19 will hopefully provide guidance about the “who,
when, and how” of using noninvasive respiratory support strategies during this pandemic.
www.ccejournal.org
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TABLE 4. Demographics, Admission and Clinical Characteristics, ICU Interventions, and
Outcomes for Subgroups
Characteristic (n [%] Unless
Otherwise Indicated)

HFNO Alone
(n = 54)

HFNO + Noninvasive
Positive-Pressure Ventilation
(n = 29)

p

Key demographics
Age, median (IQR)

65 (56-78)

67 (53-75)

0.92

Male

33 (61.1)

20 (69.0)

0.48

Race

0.43

Black

21 (38.9)

16 (55.2)

White

15 (27.8)

6 (20.7)

Other

18 (33.3)

7 (24.1)

Body mass index, median (IQR)

28.4 (24.6-32.5)

30.4 (26.3-34)

0.15

Comorbidities
Hypertension

32 (59.3)

18 (62.1)

0.80

Diabetes mellitus

30 (55.6)

14 (48.3)

0.53

Congestive heart failure

8 (14.8)

10 (34.5)

0.04

Chronic obstructive pulmonary disease/asthma

8 (14.8)

8 (27.6)

0.16

23 (16–29)

23 (18–33)

0.27

157 (106-224)

107 (84-183.5)

0.04

Key clinical characteristics and ICU interventions
Acute Physiology and Chronic Health Evaluation II score,
median (IQR)
Pao2:Fio2,a median (IQR)
Interventions
Inhaled pulmonary vasodilator

2 (3.7)

7 (24.1)

0.01

New systemic anticoagulation

16 (29.6)

8 (27.6)

0.85

New systemic steroids

21 (38.9)

17 (58.6)

0.09

4 (7.4)

5 (17.2)

0.27

17 (47.2)

11 (50.0)

0.84

1 (1.9)

1 (3.4)

1.00

Invasive mechanical ventilation

36 (66.7)

22 (75.9)

0.38

Time to intubation (d), median (IQR)

0.5 (0-1)

0 (0-1)

0.91

11 (4–30)

0.52

10 (27.8)

7 (31.8)

0.74

15 (27.8)

9 (32.1)

0.68

16 (30.8)

9 (37.5)

0.56

8 (4–13)

11.4 (4-19.5)

0.37

14.5 (9.5-25.5)

19.5 (12-28.5)

0.21

New initiation of renal replacement therapy
Prone ventilation

b

Extracorporeal membrane oxygenation
Key clinical outcomes

Ventilator days,c median (IQR)

8 (4.5-20)

Tracheostomy

d

ICU mortality
Hospital mortality

e

ICU LOS,c median (IQR)
Hospital LOS,e median (IQR)

HFNO = high-flow nasal oxygen, IQR = interquartile range, LOS = length of stay.
a
Postintubation values only.
b
Refers to % proned in 58 mechanically ventilated patients only.
c
Excludes one patient still on mechanical ventilation in the ICU as of June 30, 2020.
d
Refers to % tracheostomized in 58 mechanically ventilated patients only.
e
Excludes seven patients still hospitalized as of June 30, 2020.

6

www.ccejournal.org

2020 • Volume 2 • e0257

Original Clinical Report

ACKNOWLEDGMENTS

We thank the multidisciplinary intensivist faculty, ICU nurses,
and hospital staff at Thomas Jefferson University Hospital for
their ongoing tireless care of COVID-19 patients throughout the
pandemic.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of
this article on the journal’s website (http://journals.lww.com/ccejournal).
The authors have disclosed that they do not have any potential conflicts of
interest.
For information regarding this article, E-mail: erika.yoo@jefferson.edu

REFERENCES

1. Tobin MJ, Laghi F, Jubran A: Caution about early intubation and mechanical ventilation in COVID-19. Ann Intensive Care 2020; 10:78
2. Villarreal-Fernandez E, Patel R, Golamari R, et al: A plea for avoiding
systematic intubation in severely hypoxemic patients with COVID-19associated respiratory failure. Crit Care 2020; 24:337
3. Alhazzani W, Moller MH, Arabi YM, et al: Surviving sepsis campaign:
Guidelines on the management of critically ill adults with coronavirus
disease 2019 (COVID-19). Intensive Care Med 2020; 46:854–887
4. Hernández G, Vaquero C, Colinas L, et al: Effect of postextubation highflow nasal cannula vs noninvasive ventilation on reintubation and postextubation respiratory failure in high-risk patients: A randomized clinical
trial. JAMA 2016; 316:1565–1574
5. Maggiore SM, Idone FA, Vaschetto R, et al: Nasal high-flow versus venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. Am J Respir Crit Care Med 2014; 190:282–288
6. Frat JP, Thille AW, Mercat A, et al; FLORALI Study Group; REVA
Network: High-flow oxygen through nasal cannula in acute hypoxemic
respiratory failure. N Engl J Med 2015; 372:2185–2196
7. Wang K, Zhao W, Li J, et al: The experience of high-flow nasal cannula in
hospitalized patients with 2019 novel coronavirus-infected pneumonia in
two hospitals of Chongqing, China. Annals Intensive Care 2020; 10:37
8. Cummings MJ, Baldwin MR, Abrams D, et al: Epidemiology, clinical
course, and outcomes of critically ill adults with COVID-19 in New York
City: A prospective cohort study. Lancet 2020; 395:1763–1770
9. Zhou F, Yu T, Du R, et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective
cohort study. Lancet 2020; 395:1054–1062
10. Pronovost PJ, Angus DC, Dorman T, et al: Physician staffing patterns
and clinical outcomes in critically ill patients: A systematic review. JAMA
2002; 288:2151–2162
11. Harris PA, Taylor R, Thielke R, et al: Research electronic data capture
(REDCap)–a metadata-driven methodology and workflow process for
providing translational research informatics support. J Biomed Inform
2009; 42:377–381
12. Wang Y, Lu X, Li Y, et al: Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med 2020;
201:1430–1434
13. Grasselli G, Zangrillo A, Zanella A, et al: Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of
the Lombardy region, Italy. JAMA 2020; 323:1574–1581

Critical Care Explorations

14. Auld SC, Caridi-Scheible M, Blum JM, et al: ICU and ventilator mortality among critically ill adults with coronavirus disease 2019 [published online ahead of print May 26, 2020]. Crit Care Med. doi:
10.1097/CCM.0000000000004457
15. Bhatraju PK, Ghassemieh BJ, Nichols M, et al: Covid-19 in critically Ill
patients in the Seattle region - case series. N Engl J Med 2020; 382:2012–2022
16. Richardson S, Hirsch JS, Narasimhan M, et al; The Northwell COVID19 Research Consortium: Presenting characteristics, comorbidities, and
outcomes among 5700 patients hospitalized with COVID-19 in the New
York City area. JAMA 2020; 323:2052–2059
17. Zangrillo A, Beretta L, Scandroglio AM, et al; COVID-BioB Study Group:
Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc
2020; 22:200–211
18. Azoulay E, Lemiale V, Mokart D, et al: Effect of high-flow nasal oxygen vs
standard oxygen on 28-day mortality in immunocompromised patients
with acute respiratory failure: The HIGH randomized clinical trial. JAMA
2018; 320:2099–2107
19. Bell N, Hutchinson CL, Green TC, et al: Randomised control trial of
humidified high flow nasal cannulae versus standard oxygen in the emergency department. Emerg Med Australas 2015; 27:537–541
20. Doshi P, Whittle JS, Bublewicz M, et al: High-velocity nasal insufflation
in the treatment of respiratory failure: A randomized clinical trial. Ann
Emerg Med 2018; 72:73–83.e5
21. Jones PG, Kamona S, Doran O, et al: Randomized controlled trial of
humidified high-flow nasal oxygen for acute respiratory distress in the
emergency department: The HOT-ER study. Respir Care 2016; 61:291–299
22. Lemiale V, Mokart D, Mayaux J, et al: The effects of a 2-h trial of high-flow
oxygen by nasal cannula versus venturi mask in immunocompromised
patients with hypoxemic acute respiratory failure: A multicenter randomized trial. Crit Care 2015; 19:380
23. Ferreyro BL, Angriman F, Munshi L, et al: Association of noninvasive
oxygenation strategies with all-cause mortality in adults with acute
hypoxemic respiratory failure: A systematic review and meta-analysis.
JAMA 2020; 324:57–67
24. Gattinoni L, Chiumello D, Caironi P, et al: COVID-19 pneumonia:
Different respiratory treatments for different phenotypes? Intensive Care
Med 2020; 46:1099–1102
25. Cheria R, Chandra B, Tung ML, et al: COVID-19 conundrum: Clinical
phenotyping based on pathophysiology as a promising approach to guide
therapy in a novel illness. Eur Respir J 2020; 56:2002135
26. Li J, Fink JB, Ehrmann S: High-flow nasal cannula for COVID-19 patients:
Low risk of bio-aerosol dispersion. Eur Respiratory J 2020; 55:2000892
27. Agarwal A, Basmaji J, Muttalib F, et al: High-flow nasal cannula for acute
hypoxemic respiratory failure in patients with COVID-19: Systematic
reviews of effectiveness and its risks of aerosolization, dispersion, and
infection transmission [published online ahead of print June 15, 2020].
Can J Anesth. doi: 10.1007/s12630-020-01740-2
28. Lai X, Wang M, Qin C, et al: Coronavirus disease 2019 (COVID-2019)
infection among health care workers and implications for prevention
measures in a tertiary hospital in Wuhan, China. JAMA Network Open
2020; 3:e209666
29. Frat JP, Brugiere B, Ragot S, et al: Sequential application of oxygen therapy
via high-flow nasal cannula and noninvasive ventilation in acute respiratory failure: An observational pilot study. Respir Care 2015; 60:170–178
30. Brochard L, Slutsky A, Pesenti A: Mechanical ventilation to minimize
progression of lung injury in acute respiratory failure. Am J Respir Crit
Care Med 2017; 195:438–442

www.ccejournal.org

7

